New insider activity at Johnson & Johnson ( (JNJ) ) has taken place on February 27, 2025.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
VP Corporate Controller Robert J Decker recently executed a significant transaction by selling 6,999 shares of Johnson & Johnson stock, amounting to a total value of $1,160,994.
Recent Updates on JNJ stock
In the last 24 hours, Johnson & Johnson has experienced notable developments impacting its stock. The company announced positive results from the Phase 3 ASTRO study of TREMFYA for ulcerative colitis, which showed significant improvements compared to placebo, aligning with FDA-approved regimens. Additionally, J&J is facing a legal challenge over its $10 billion baby powder settlement proposal, as it attempts to resolve lawsuits through a subsidiary’s bankruptcy. The company is also planning to sell its stroke care business, Cerenovus, as part of a strategy to reorganize its medtech unit. Financially, J&J’s Q4 earnings call highlighted robust growth in its Innovative Medicine and MedTech sectors, though earnings were impacted by STELARA biosimilars, acquisitions, and challenges in the Chinese market. Guggenheim raised its price target for J&J, citing the company’s ability to meet or slightly exceed expectations and its potential for sustained growth through its pipeline in oncology, immunology, and neuroscience.
More about Johnson & Johnson
YTD Price Performance: 15.77%
Average Trading Volume: 8,791,142
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: $399.9B